Llwytho...
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or dec...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
American Society of Hematology
2014
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4208285/ https://ncbi.nlm.nih.gov/pubmed/25224413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-582809 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|